

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 April 2003 (10.04.2003)

PCT

(10) International Publication Number
WO 03/028531 A2

- (51) International Patent Classification⁷: **A61B**
- (21) International Application Number: PCT/US02/30485
- (22) International Filing Date:
26 September 2002 (26.09.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
09/966,515 28 September 2001 (28.09.2001) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 09/966,515 (CON)
Filed on 28 September 2001 (28.09.2001)
- (71) Applicant (for all designated States except US): **ON-COMEDX, INC.** [US/US]; 23 Wellington Drive, Long Valley, NJ 07853 (US).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): **KOPRESKI, Michael** [US/US]; 23 Wellington Drive, Long Valley, NJ 07853 (US).
- (74) Agent: **NOONAN, Kevin**; McDonnell Boehnen Hulbert & Berghoff, 300 South Wacker Drive, Chicago, IL 60606 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DETECTION OF TUMOR RNA IN PLASMA AND SERUM

(57) Abstract: The methods of the invention detect epidermal growth factor RNA, epidermal growth factor receptor RNA, her-2/neu RNA, c-myc RNA, heterogeneous nuclear ribonucleoprotein A2/B1 or any combination thereof in blood plasma, serum, and other bodily fluids. The inventive methods are useful for detection, diagnosis, monitoring, treatment, or evaluation of neoplastic disease.

WO 03/028531 A2

DETECTION OF TUMOR RNA IN PLASMA AND SERUM

This application is a continuation-in-part of U.S. Patent Application, Serial No. 09/155,152, filed September 22, 1998, the entire disclosure of which is hereby incorporated by reference.

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention relates to methods for detecting tumor-derived or tumor-associated mammalian ribonucleic acid (RNA) in bodily fluids such as blood plasma and serum obtained from an animal, most preferably a human. Specifically, the invention is directed towards methods for detecting RNA in bodily fluids from a human bearing a premalignant lesion or a malignancy, ranging in severity from localized neoplasia to metastatic disease. The methods of the invention are particularly drawn to detecting RNA encoding all or a portion of particular genes associated with neoplastic growth, development, or pathogenesis. In particular, these methods are drawn to genes associated with tumor growth factors such as tyrosine kinase mediated growth factors (*for example*, epidermal growth factor, EGF) and their receptors (*for example*, epidermal growth factor receptor (EGFr), and her-2/neu), as well as oncogenes such as c-myc oncogene. The methods of the invention are further particularly drawn to detecting RNA derived or associated with tumor-associated ribonucleoprotein, such as but not limited to heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP A2/B1) and associated ribonucleoprotein. In view of the essential role of RNA in expressing genes and producing proteins encoded thereby, detection and monitoring of RNA provides a convenient and reliable method for assessing and monitoring gene expression associated with neoplastic disease, thereby enabling the detection, diagnosis, monitoring, evaluation, and prognosticating of cancer and premalignancy.

2. Background of the Related Art

The pathogenesis and regulation of cancer is dependent upon gene expression, comprising production and translation of RNA to produce proteins involved with a variety of cellular processes, such as cell proliferation, regulation, and death. Furthermore, some gene expression, resulting in the existence of RNA and the proteins translated therefrom in cells and tissues, although not necessarily involved in neoplastic pathogenesis or regulation, may comprise a phenotype of recognizable characteristics for particular neoplasms, *for example*, either by being expressed at elevated levels or by being inappropriately expressed in said cells or tissues.

Tyrosine kinase-mediated growth factors and their receptors such as epidermal growth factor (EGF), epidermal growth factor receptor (EGFr), and her-2/*neu*, play important roles in the growth of many epithelial cancers and their response to insult or injury. Oncogenes such as c-myc play important roles in the pathogenesis of many cancers. Other proteins, such as hnRNP A2/B1 and associated ribonucleoproteins including hnRNP A2 (heterogeneous nuclear ribonucleoprotein A2) and hnRNP B1 (heterogeneous nuclear ribonucleoprotein B1) are overexpressed early in the development of some cancers. Detection of RNA encoding EGF, EGFr her-2/*neu*, c-myc or hnRNP A2/B1 provides a method for detecting and monitoring a wide spectrum of cancers and premalignancies, and can have prognostic significance. Tyrosine kinase-mediated growth factors and their receptors further provide potential targets for cancer therapies such as monoclonal antibody-based therapies (*for example*, herceptin for her-2/*neu* and CA-225 for EGFr), small molecule therapies and tyrosine kinase inhibitors, as well as vaccine therapies. Detection of EGF, EGFr and her-2/*neu* RNA can thus provide methods for selecting and monitoring patients for such therapies.

RNA associated with cancer and premalignant or neoplastic states, such as RNA encoding EGF, EGFr her-2/*neu*, c-myc or hnRNP A2/B1 are referred to herein as tumor-derived or tumor-associated RNA. Co-owned and co-pending U.S. Patent Application Serial No. 09/155,152, incorporated by reference herein in its entirety, provides methods by which

5 mammalian tumor-associated or tumor-derived RNA in bodily fluids such as plasma and serum can be detected and utilized for detecting, monitoring, or evaluating cancer or premalignant conditions. U.S. Patent Application Serial No. 09/155,152, incorporated by reference herein in its entirety, further taught that tumor-associated or tumor-derived RNAs include *erb-B-1* mRNA (also known as epidermal growth factor receptor mRNA), her-2/*neu* mRNA (also known as *erb-*

10 B-2 mRNA), c-myc mRNA, and hnRNP A2/B1 associated RNA were advantageously detected in bodily fluids such as blood plasma or serum.

RNA encoding EGF, EGFr, her-2/*neu*, c-myc, and hnRNP A2/B1 being recognized as tumor-associated RNAs, there is a newly-appreciated need in the art to identify premalignant or malignant states characterized by said RNA in animals including humans by detecting said RNA

15 in bodily fluids such as blood plasma or serum.

SUMMARY OF THE INVENTION

20 The present invention provides methods for detecting EGF RNA, EGFr RNA, her-2/*neu* RNA, and hnRNP A2/B1 RNA, or any combination thereof, in bodily fluids, preferably in blood and most preferably in blood plasma and serum, and in other bodily fluids including but not limited to urine, effusions, ascites, saliva, cerebrospinal fluid, cervical secretions, vaginal secretions, endometrial secretions, gastrointestinal secretions, sputum and bronchial secretions,

25 and breast fluid and associated lavages and washings. The inventive methods comprise detecting

extracellular mammalian tumor-associated or tumor-derived RNA such as EGF RNA, EGFr RNA, her-2/neu RNA c-myc RNA or hnRNP A2/B1 RNA, or any combination thereof, in said bodily fluids.

In preferred embodiments, the methods of the invention comprise the step of amplifying
5 and detecting extracellular EGF RNA, EGFr RNA, her-2/neu RNA, c-myc RNA, and/or hnRNP A2/B1 RNA or any combination thereof from bodily fluids of an animal, most preferably a human.

In particularly preferred embodiments, the present invention provides methods for detecting EGF RNA, or EGFr RNA, or her-2/neu RNA, or c-myc RNA, or hnRNP A2/B1 RNA,
10 or any combination thereof in blood or a blood fraction, including plasma and serum, and other bodily fluids. In these embodiments, the method comprises the steps of extracting mammalian RNA from blood, plasma, serum, or other bodily fluid, wherein a fraction of the extracted RNA comprises extracellular EGF RNA, EGFr RNA, her-2/neu RNA, c-myc RNA, or hnRNP A2/B1 RNA; or any combination thereof; *in vitro* amplifying RNA or cDNA corresponding thereto
15 encoding EGF, EGFr, her-2/neu , c-myc, or hnRNP A2/B1 or any combination thereof; and detecting the amplified products produced from said mRNA or cDNA.

In a first aspect of this embodiment, the present invention provides methods for detecting EGF RNA, EGFr RNA, her-2/neu RNA, c-myc RNA, hnRNP A2/B1 or any combination thereof in blood or blood fractions, including plasma and serum, in an animal, most preferably a human.
20 Said methods advantageously permit detection, diagnosis, monitoring, treatment, or evaluation of proliferative disorders, particularly stages of neoplastic disease, including premalignancy, early cancer, non-invasive cancer, carcinoma *in-situ*, invasive cancer, metastatic cancer and advanced cancer, as well as benign neoplasms. In this aspect, the method comprises the steps of extracting

mammalian RNA from blood or blood plasma or serum, *in vitro* amplifying qualitatively or quantitatively a fraction of the extracted RNA or the corresponding cDNA wherein said fraction comprises EGF-, EGFr-, her-2/neu-, c-myc-, or hnRNP A1/A2-encoding RNA or combination thereof, and detecting the amplified products of said RNA or cDNA.

5 The invention in a second aspect provides methods for detecting EGF-, EGFr-, her-2/neu-, c-myc-, or hnRNP A2/B1-encoding RNA or any combination thereof in any bodily fluid. Preferably, said bodily fluid is whole blood, blood plasma, serum, urine, effusions, ascitic fluid, amniotic fluid, saliva, cerebrospinal fluid, cervical secretions, vaginal secretions, endometrial secretions, gastrointestinal secretions, bronchial secretions including sputum, secretions or
10 washings from the breast, and other associated tissue washings from an animal, most preferably a human. In this aspect, the method comprises the steps of extracting mammalian RNA from the bodily fluid; *in vitro* amplifying in a qualitative or quantitative fashion a fraction of the extracted RNA, wherein said fraction comprises extracellular EGF RNA, EGFr RNA, her-2/neu RNA, c-myc RNA, hnRNP A2/B1 RNA or any combination thereof, or more preferably cDNA
15 corresponding thereto, and detecting the amplified product of said RNA or cDNA.

In these embodiments, the inventive methods are particularly advantageous for detecting, diagnosing, monitoring, treating, or evaluating proliferative disorders in an animal, most preferably a human, said proliferative disorders particularly including stages of neoplastic disease, including premalignancy, early cancer, non-invasive cancer, carcinoma-in-situ, invasive
20 cancer, metastatic cancer and advanced cancer as well as benign neoplasm.

Thus, in another aspect the invention provides methods for evaluating an animal, most preferably a human, for premalignant or malignant states, disorders, or conditions. The inventive methods comprise detecting extracellular mammalian tumor-associated or tumor-derived RNA

including EGF RNA, EGFr RNA, her-2/neu RNA c-myc RNA and hnRNP A2/B1 RNA or any combination thereof in bodily fluids, preferably blood and most preferably blood plasma and serum as well as in other bodily fluids, preferably urine, effusions, ascites, amniotic fluid, saliva, cerebrospinal fluid, cervical, vaginal, and endometrial secretions, gastrointestinal secretions, bronchial secretions, breast fluid, and associated tissue washings and lavages.

The methods of the invention are also useful for identifying EGF-, EGFr-, her-2/neu-, c-myc-, or hnRNP A2/B1-expressing cells or tissue in an animal, most preferably a human. In these embodiments, detection of an *in vitro* amplified product of EGF RNA, EGFr RNA, her-2/neu RNA, c-myc RNA, or hnRNP A2/B1 RNA or cDNA corresponding thereto using the methods of the invention indicates the existence of EGF, EGFr, her-2/neu, c-myc, or hnRNP A2/B1-expressing cells or tissue in a human.

The invention further provides diagnostic kits for detecting EGF RNA, EGFr RNA, her-2/neu RNA, c-myc RNA, hnRNPA2/B1 RNA or any combination thereof in bodily fluid, preferably blood plasma or serum, wherein the kit comprises oligonucleotide primers, probes, or both primers and probes for amplifying and detecting said EGF RNA, EGFr RNA, her-2/neu RNA, c-myc RNA, hnRNPA2/B1 RNA or any combination thereof or cDNA derived therefrom. In advantageous embodiments, the kit may further comprise instructions and reagents for performing methods for extracting RNA from the bodily fluid, reverse-transcribing said RNA into cDNA or reagents for performing *in vitro* amplification.

In preferred embodiments of the inventive methods, EGF RNA, EGFr RNA, her-2/neu RNA, c-myc RNA, hnRNP A2/B1 RNA or any combination thereof is extracted from whole blood, blood plasma or serum, or other bodily fluids using any effective extraction method including but not limited to gelatin extraction methods; silica, glass bead, or diatom extraction

methods; guanidinium thiocyanate acid-phenol based extraction methods; guanidinium thiocyanate acid based extraction methods; methods using centrifugation through cesium chloride or similar gradients; phenol-chloroform based extraction methods; or other commercially available RNA extraction methods. In this aspect of the invention, RNA is
5 extracted from plasma, serum, or other bodily fluid. In other aspects of the invention, extraction may alternatively be performed using probes that specifically hybridize to a particular RNA.

In preferred embodiments of the inventive methods, EGF RNA, EGFr RNA, her-2/neu RNA, c-myc RNA, hnRNP A2/B1 RNA or any combination thereof, or more preferably cDNA derived therefrom is amplified using an *in vitro* amplification method such as reverse
10 transcriptase polymerase chain reaction (RT-PCR); ligase chain reaction; DNA signal amplification; amplifiable RNA reporters; Q-beta replication; transcription-based amplification; isothermal nucleic acid sequence based amplification; self-sustained sequence replication assays; boomerang DNA amplification; strand displacement activation; cycling probe technology; or any combination or variation thereof.

15 In preferred embodiments of the inventive methods, amplification products of EGF RNA, EGFr RNA, her-2/neu RNA, c-myc RNA, hnRNP A2/B1 RNA or any combination thereof, or more preferably cDNA produced therefrom, are detected using a detection method such as gel electrophoresis; capillary electrophoresis; conventional enzyme-linked immunosorbent assay (ELISA) or modifications thereof, such as amplification using biotinylated or otherwise modified
20 primers; nucleic acid hybridization using specific labeled probes, such as fluorescent-, radioisotope-, or chromogenically-labeled probes; Southern blot analysis; Northern blot analysis; electrochemiluminescence; laser-induced fluorescence; reverse dot blot detection; and high-performance liquid chromatography.

In particularly preferred embodiments of the inventive methods, RNA is converted to cDNA using reverse transcriptase following extraction of RNA from a bodily fluid and prior to amplification.

The methods of the invention are advantageously used for providing a diagnosis of, or as
5 a predictive indicator for determining risk for a human of developing a proliferative, premalignant, neoplastic, or malignant disease comprising or characterized by cells expressing EGF RNA, EGFr RNA, her-2/neu RNA, c-myc RNA, hnRNP A2/B1 RNA or any combination thereof.

The methods of the invention are particularly useful for providing a diagnosis of or for
10 identifying in animals, particularly humans, who are at risk for developing or who have developed malignancy or premalignancy of cells comprising epithelial tissues. Most preferably, malignant or premalignant diseases, conditions, or disorders advantageously detected or diagnosed using the methods of the invention are diseases or disorders of breast, ovaries, lung, cervix, colorectal, stomach, pancreas, bladder, endometrium, kidney, head and neck, and
15 esophageal cancers, and premalignancies and carcinoma *in-situ* such as bronchial dysplasia, atypical hyperplasia of the breast, ductal carcinoma in-situ, colorectal adenoma, atypical endometrial hyperplasia, and Barrett's esophagus.

In certain preferred embodiments of the methods of the invention, EGF RNA, EGFr RNA, her-2/neu RNA, c-myc RNA, hnRNP A2/B1 RNA or combinations thereof, or cDNA
20 derived therefrom is amplified in a quantitative manner, thereby enabling quantitative comparison of said RNA present in a bodily fluid such as blood plasma or serum from a human. In these embodiments, the amount of extracellular EGF RNA, EGFr RNA, her-2/neu RNA, c-myc RNA, or hnRNP A2/B1 RNA or combinations thereof are detected in an individual and

compared with a range of amounts of said extracellular RNA detected in the bodily fluid in a plurality of humans known to have a premalignant or malignant disease, or known to be free from a premalignant or malignant disease.

The invention further provides methods for identifying individuals having an EGF-,
5 EGF α -, her-2/neu-, c-myc-, or hnRNP A2/B1-expressing malignancy or premalignancy, or a malignancy expressing any combination of said RNAs, thereby permitting rational, informed treatment options to be used for making therapeutic decisions. In particular, the methods of the invention are useful in identifying individuals having a premalignancy or malignancy that would benefit from a therapy directed at cells and tissues that express EGF, EGF α , her-2/neu-, c-myc-,
10 or hnRNP A2/B1, such as monoclonal antibody therapy, anti-sense therapy, and vaccine therapy.

Another advantage of the use of the methods of the invention is that the methods can produce markers for assessing the adequacy of anticancer therapies such as surgical intervention, chemotherapy, biotherapy such as monoclonal antibody therapy or vaccines, anti-angiogenic therapy, and radiation therapy, and is also useful for determining whether additional or more
15 advanced therapy is required. The invention therefore provides methods for developing a prognosis in such patients.

The methods of the invention also permit identification or analysis of EGF RNA, EGF α RNA, her-2/neu RNA, c-myc RNA, hnRNP A2/B1 RNA or any combination thereof, either qualitatively or quantitatively, in the blood or other bodily fluid of an animal, most preferably a
20 human that has completed therapy, as an early indicator of relapsed cancer, impending relapse, or treatment failure.

Specific preferred embodiments of the present invention will become evident from the following more detailed description of certain preferred embodiments and the claims.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

5 The invention provides methods for detecting epidermal growth factor (EGF) RNA, epidermal growth factor receptor (EGFr) RNA, her-2/neu RNA, c-myc RNA, or heterogeneous nuclear ribonucleoprotein A2/B1 (hnRNP A2/B1) RNA, or any combination thereof in bodily fluids in an animal, most preferably a human. These methods are useful, *inter alia*, for detecting cancerous or precancerous cells in the animal.

10 In preferred embodiments of the methods of the invention, mammalian RNA in a bodily fluid, a portion thereof comprising extracellular EGF RNA, EGFr RNA, her-2/neu RNA, c-myc RNA hnRNP A2/B1 RNA, or any combination thereof is extracted from said bodily fluid. This extracted RNA is then amplified, either after conversion into cDNA or directly, using *in vitro* amplification methods in either a qualitative or quantitative manner, and using oligonucleotide
15 primers specific for EGF RNA, EGFr RNA, her-2/neu RNA, c-myc RNA or hnRNP A2/B1 RNA or any combination thereof, or cDNA derived therefrom, to form a product DNA fragment having a size and sequence complexity specific for each of said specific RNAs. The amplified product is then detected in either a qualitative or a quantitative manner.

20 In the practice of the methods of the invention, mammalian RNA, a portion of which comprises extracellular EGF RNA, EGFr RNA, her-2/neu RNA, c-myc RNA, hnRNP A2/B1 RNA, or any combination thereof, is extracted from a bodily fluid, including but not limited to whole blood, plasma, serum, urine, effusions, ascitic fluid, saliva, cerebrospinal fluid, cervical secretions, vaginal secretions, endometrial secretions, amniotic fluid, gastrointestinal secretions,

bronchial secretions including sputum, breast fluid or secretions or washings. Extraction can be performed using, *for example*, extraction methods described in co-owned and co-pending U.S. Patent Application Serial No. 09/155,152, the entire disclosure of which is hereby incorporated by reference and include but are not limited to gelatin extraction methods; silica, glass bead, or
5 diatom extraction methods; guanidinium thiocyanate acid-phenol based extraction methods; guanidinium thiocyanate acid based extraction methods; methods using centrifugation through cesium chloride or similar gradients; phenol-chloroform based extraction methods; or other commercially available RNA extraction methods. Alternatively, extraction may be performed using probes that specifically hybridize to a particular RNA, more preferably using isolation
10 methods dependent thereupon, *for example* chromatographic methods and methods for capturing RNA hybridized to said specific primers. In a preferred embodiment, the bodily fluid is either blood plasma or serum. It is preferred, but not required, that blood be processed soon after drawing, and preferably within three hours, to minimize any degradation in the sample. In a preferred embodiment, blood is first collected by venipuncture and kept on ice until use.
15 Preferably within 30 minutes of drawing the blood, serum is separated by centrifugation, for example at 1100 x g for 10 minutes at 4 degrees centigrade. When using plasma, blood should not be permitted to coagulate prior to separation of the cellular and acellular blood components. Serum or plasma can be frozen, for example at -70 degrees centigrade after separation from the cellular portion of blood, until use. When using frozen blood plasma or serum, the frozen
20 plasma or serum is rapidly thawed, for example in a water bath at 37 degrees centigrade, and RNA is extracted therefrom without undue delay, most preferably using a commercially available kit (for example the Perfect RNA Total RNA Isolation Kit obtained from Five Prime - Three Prime, Inc., Boulder, Colorado), according to the manufacturer's instructions. Other

alternative and equivalent methods of RNA extraction are further provided in co-owned and co-pending U.S. Patent Application Serial No. 09/155,152, incorporated herein by reference in its entirety.

Following extraction of RNA from a bodily fluid that contains EGF mRNA, EGFr mRNA, her-2/neu mRNA, c-myc mRNA, or hnRNP A2/B1 RNA, or any combination thereof, the EGF RNA, EGFr RNA, her-2/neu RNA, c-myc RNA, or hnRNP A2/B1 RNA or cDNA derived therefrom is amplified *in vitro*. Applicable amplification assays are detailed in co-owned and co-pending U.S. Patent Application Serial No. 09/155,152, as herein incorporated by reference, and include but are not limited to reverse transcriptase polymerase chain reaction (RT-PCR), ligase chain reaction, DNA signal amplification, amplifiable RNA reporters, Q-beta replication, transcription-based amplification, boomerang DNA amplification, strand displacement activation, cycling probe technology, isothermal nucleic acid sequence based amplification, and other self-sustained sequence replication assays.

In preferred embodiments of the methods of the invention, RNA encoding EGF, EGFr, her-2/neu, c-myc, or hnRNP A2/B1, or any combination thereof is converted into cDNA using reverse transcriptase prior to *in vitro* amplification using methods known in the art. For example, a sample such as 10 microL extracted serum RNA is reverse-transcribed in a 30 microL volume containing 200 Units of Moloney murine leukemia virus (MMLV) reverse transcriptase (Promega, Madison, WI), a reaction buffer supplied by the manufacturer, 1 mM each dNTPs, 0.5 micrograms random hexamer oligonucleotide primers, and 25 Units of RNAsin (Promega, Madison, WI). Reverse transcription is typically performed under an overlaid mineral oil layer to inhibit evaporation, and incubated at room temperature for 10 minutes followed by incubation at 37 degrees C for one hour. In another embodiment, reverse transcription is performed by the

method of Rajagopal *et al.* (1995, *Int. J. Cancer* 62: 661-667), herein incorporated by reference in its entirety, or by the method of Dahiya *et al.* (1996, *Urology* 48: 963-970), herein incorporated by reference in its entirety.

Amplification oligonucleotide primers are selected to be specific for amplifying the nucleic acid of interest. In a preferred embodiment, amplification is performed by RT-PCR, wherein oligonucleotide primers are based upon gene or cDNA sequences using methods known to the art. In preferred embodiments, preferred oligonucleotide primers have nucleotide sequences as follows:

For epidermal growth factor (EGF) mRNA RT-PCR, the preferred primers are those as described by Rajagopal *et al.* (1995, *Int. J. Cancer* 62: 661-667), herein incorporated by reference in its entirety, wherein EGF primers (commercially available from Clontech, Palo Alto, California) have the sequence

5' TCTCAACACATGCTAGTGGCTGAAATCATGG (5' Primer; SEQ ID No. 1)

5' TCAATATACATGCACACACCATCATGGAGGC (3' Primer; SEQ ID No. 2).

For EGF mRNA RT-PCR, other preferred primers are those as described by Dahiya *et al.* (1996, *Urology* 48: 963-970), herein incorporated by reference in its entirety, wherein primers for PCR of EGF cDNA have the sequence

5' TCTCAACACATGCTAGTGGCTGAAATCATGG (Sense; SEQ ID No. 3)

5' TCAATATACATGCACACACCATCATGGAGGC (Antisense; SEQ ID No. 4)

It is further to be understood that other primers for amplification of EGF cDNA or mRNA as determined using methods of the art are suitable for use in the invention, for example but not limitation primers described by LeRiche *et al.* (1996, *J. Clin. Endocrinol. Metab.* 81: 656-662), or Pfeiffer *et al.* (1997, *Int. J. Cancer* 72: 581-586), these references incorporated herein by
5 reference in their entirety.

For epidermal growth factor receptor (EGFr) mRNA RT-PCR, the preferred primers are those described by De Luca *et al.* (2000, *Clin. Cancer Res.* 6: 1439-1444), herein incorporated by reference in its entirety, wherein primers for nested PCR of EGFr cDNA have the sequences:

10 Primer A: 5' TCTCAGCAACATGTCGATGG (SEQ ID No. 5)

Primer B: 5' TCGCACTTCTTACACTTGCG (SEQ ID No. 6)

Primer C: 5' TCACATCCATCTGGTACGTG (SEQ ID No. 7)

It is further to be understood that other primers for amplification of EGFr cDNA or mRNA as determined using methods of the art are suitable for use in the invention, *for example*, primers
15 described by LeRiche *et al.* (1996, *J. Clin. Endocrinol. Metab.* 81: 656-662) and by Dahiya *et al.* (1996, *Urology* 48: 963-970), these references herein incorporated by reference in their entirety.

It is further to be understood that primers for amplification of altered, rearranged, deleted or splice mutated, or otherwise mutated EGFr gene mRNA or cDNA as determined using methods known to the art are suitable for use in the invention, whereby said mRNA is thereby detected in
20 a bodily fluid, *for example* by using the primers as described by Schlegel *et al.* (1994, *Int. J. Cancer* 56: 72-77) or by Worm *et al.* (1999, *Hum. Pathol.* 30: 222-227), these references herein incorporated by reference in their entirety.

For her-2/neu mRNA RT-PCR, the preferred primers are those described Pawlowski *et al.* (2000, *Cancer Detect. Prev.* 24: 212-223), herein incorporated by reference in its entirety, wherein primers for conventional PCR of her-2/neu cDNA have the sequence:

5' GAGACGGAGCTGAGGAAGGTGAAG (Sense; SEQ ID No. 8)

5 5' TTCCAGCAGGTCAGGGATCTCC (Antisense; SEQ ID No. 9)

and wherein primers for real-time quantitative RT-PCR using a TaqMan fluorogenic probe (Perkin-Elmer) have the sequence:

5' CAACCAAGTGAGGCAGGTCC (Sense; SEQ ID No. 10)

5' GGTCTCCATTGTCTAGCACGG (Antisense; SEQ ID No. 11)

10 5' AGAGGCTGCGGATTGTGCGA (TaqMan probe; SEQ ID No. 12)

wherein the TaqMan probe contains a 5' FAM (6-carboxy-fluorescein) reporter dye and a 3' TAMRA (6-carboxy-tetramethyl-rhodamine) quencher dye and a 3' phosphate.

It is further understood that other primers for amplification of her-2/neu cDNA or mRNA are suitable for use as designed using methods known to the art, for example but not limitation
15 primers described by Walch *et al.* (2001, *Lab. Invest.* 81: 791-801), Sarkar *et al.* (1993, *Diagn. Mol. Pathol.* 2: 210-218), Gebhardt *et al.* (1998, *Biochem. Biophys. Res. Comm.* 247: 319-323), Revillion *et al.* (1997, *Clin. Chem.* 43: 2114-2120), or Schneeberger *et al.* (1996, *Anticancer Res.* 16: 849-852), these references incorporated herein by reference in their entirety.

20 For c-myc mRNA RT-PCR, the preferred primers are those described by Kraehn *et al.* (2001, *Br. J. Cancer* 84: 72-79), herein incorporated by reference in its entirety, wherein primers for PCR of c-myc cDNA are commercially available (Stratagene, Heidelberg, Germany), and have the sequence

5' CCAGCAGCGACTCTGAGG

(upstream primer; SEQ ID No. 13)

5' CCAAGACGTTGTGTGTTC

(downstream primer; SEQ ID No. 14)

It is further understood that other primers for qualitative or quantitative amplification of c-myc cDNA or mRNA are suitable for use as designed using methods known to the art, for example but not limitation primers described by Gamberi *et al.* (1998, *Oncology* 55: 556-563), Sagawa *et al.* (2001, *Cancer Letters* 168: 45-50), Christoph *et al.* (1999, *Int. J. Cancer* 84: 169-173), and Latil *et al.* (2000, *Int. J. Cancer* 89: 172-176), these references incorporated herein by reference in their entirety.

10 For hnRNP A2/B1 RNA RT-PCR, the preferred primers are those described by Zhou *et al.* (1996, *J. Biol. Chem.* 271: 10760-10766), herein incorporated by reference in its entirety, wherein primers for PCR of hnRNP A2/B1 associated cDNA have the sequence

5' GAGTCCGGTTCGTGTTCGTC

(SEQ ID No. 15)

5' TGGCAGCATCAACCTCAGC

(SEQ ID No. 16)

15 It is further understood that other primers for qualitative or quantitative amplification of hnRNP A2/B1 cDNA or RNA, or for amplification of associated RNA such as hnRNP A2 RNA or cDNA and hnRNP B1 RNA or cDNA, are suitable for use as designed using methods known to the art.

20 In one example of a preferred embodiment, RNA is harvested from approximately 1.75 mL aliquots of serum or plasma, and RNA extracted therefrom by the Perfect RNA Total RNA Isolation Kit (Five Prime – Three Prime, Inc., Boulder, Colorado) according to manufacturer's

instructions. From this extracted RNA preparation, 10 - 20 microliters are reverse transcribed to cDNA as described above.

In a preferred embodiment, RT-PCR for EGF mRNA is performed by the method of Rajagopal *et al.* (1995, *Int. J. Cancer* 62: 661-667), incorporated herein by reference in its entirety, using 19 microliters of the EGF cDNA in a final volume of 100 microliters in a reaction mixture containing 2.5U of AmpliTaq DNA Polymerase (Perkin Elmer Corp., Foster City, California), 80 microliters of PCR buffer containing 10 mM Tris-HCl, pH 8.3, 50 mM KCl, 1.5 mM MgCl₂, 400 microM each dNTP, and 0.125 microM each of Primer SEQ ID No. 1 and Primer SEQ ID No. 2 identified above. The mixture is amplified in a single-stage reaction in a thermocycler under a temperature profile consisting of an initial 5 minute incubation at 94 degrees C, followed by 40 cycles of denaturation at 94 degrees C for 10 seconds, annealing at 63 degrees C for 30 seconds, and extension at 72 degrees C for 30 seconds, followed by a final extension at 72 degrees C for 10 minutes. Detection of the amplified product is achieved, for example by gel electrophoresis through a 3% Tris-borate-EDTA (TBE) agarose gel, using ethidium bromide staining for visualization and identification of the product fragment.

In alternative preferred embodiments, qualitative or quantitative amplification for EGF mRNA is performed by other methods known to the art, *for example*, methods as described by Dahiya *et al.* (1996, *Urology* 48: 963-970); LeRiche *et al.* (1996, *J. Clin. Endocrinol. Metab.* 81: 656-662); or Pfeiffer *et al.* (1997, *Int. J. Cancer* 72: 581-586), wherein these references are incorporated by reference herein in their entirety.

In a preferred embodiment, PCR amplification of EGFr cDNA is performed by the method of De Luca *et al.* (2000, *Clin. Cancer Res.* 6: 1439-1444), herein incorporated by reference in its entirety. Eight microL of EGFr cDNA is used in a 25 microL reaction buffer

containing 10 mM Tris-HCl, 1.5 mM MgCl₂, 50 mM KCl, 0.25 mM each dNTPs, 0.5 U Taq Gold polymerase (Perkin-Elmer), and 10 picomoles each of Primer A (SEQ ID No. 5, identified above) and Primer B (SEQ ID No. 6, identified above). The mixture is amplified in a two stage reaction in a thermocycler. In the first stage reaction, PCR is performed for 30 cycles under a temperature profile consisting of an initial 10 minute incubation at 94 degrees C, followed by 5 cycles of denaturation at 94 degrees C for 30 seconds, annealing at 60 degrees C for 45 seconds, and extension at 72 degrees C for 45 seconds, followed by 25 cycles of denaturation at 94 degrees C for 30 seconds, annealing at 55 degrees C for 45 seconds, and extension at 72 degrees C for 45 seconds, with the extension lengthened to 10 minutes during the last cycle. One microliter of the first stage product is then used for the second stage nested PCR in a mixture prepared as in the first stage except that the primers used are now Primer A (SEQ ID No. 5, identified above) and Primer C (SEQ ID No. 7, identified above). In the second stage reaction, nested PCR is performed for 35 cycles under a temperature profile consisting of an initial 10 minute incubation at 94 degrees C, followed by 5 cycles of denaturation at 94 degrees C for 30 seconds, annealing at 60 degrees C for 45 seconds, and extension at 72 degrees C for 45 seconds, followed by 30 cycles of denaturation at 94 degrees C for 30 seconds, annealing at 55 degrees C for 45 seconds, and extension at 72 degrees C for 45 seconds, with the extension lengthened to 10 minutes during the last cycle. The amplified product can then be detected by gel electrophoresis through a 1.5% agarose gel with visualization by ethidium bromide staining. The amplified product can further be hybridized to an EGFr cDNA probe and visualized for example using streptavidin-alkaline phosphatase-coupled enhanced chemiluminescence (New England Biolabs, Beverly, Massachusetts).

In alternative preferred embodiments, qualitative or quantitative amplification for EGFr mRNA or cDNA, including EGFr mRNA or cDNA corresponding to a mutated or altered EGFr gene, is performed by methods known to the art, *for example*, methods described by LeRiche *et al.* (1996, *J. Clin. Endocrinol. Metab.* 81: 656-662), Dahiya *et al.* (1996, *Urology* 48: 963-970),
5 Schlegel *et al.* (1994, *Int. J. Cancer* 56: 72-77), and Worm *et al.* (1999, *Hum. Pathol.* 30: 222-227), these references herein incorporated by reference in their entirety.

In a preferred embodiment, PCR amplification of her-2/neu cDNA is performed by the method of Pawlowski *et al.* (2000, *Cancer Detection Prev.* 24: 212-223), herein incorporated by reference in its entirety, adapted as follows. A PCR reaction mixture is prepared in a 50 microL
10 final volume containing 5 microL cDNA, 1.5 mM MgCl₂, 0.8 mM of each dNTP, 2 Units Taq DNA polymerase (Eurobio, Les Ulis, France), and 0.4 microM each her-2/neu primers (SEQ ID Nos. 8 and 9). PCR is performed in a thermocycler for 45 cycles under a temperature profile consisting of an initial denaturation at 94 degrees C for 5 minutes, followed by denaturation at 94 degrees C for 30 seconds, annealing at 60 degrees C for 20 seconds, and extension at 72 degrees
15 C for 60 seconds, with a final extension at 72 degrees C for 8 minutes. Detection of the amplified product is achieved, for example by gel electrophoresis through a 1.5% agarose gel, using ethidium bromide staining for visualization and identification of the product fragment.

In alternative preferred embodiments, qualitative or quantitative amplification for her-2/neu mRNA or cDNA is performed by other methods known to the art, *for example*, methods as
20 described by Pawlowski *et al.* (2000, *Cancer Detection Prev.* 24: 212-223) for real-time quantitative RT-PCR, Walch *et al.* (2001, *Lab. Invest.* 81: 791-801), Sarkar *et al.* (1993, *Diagn Mol. Pathol.* 2: 210-218), Gebhardt *et al.* (1998, *Biochem. Biophys. Res. Comm.* 247: 319-323),

Revillion *et al.* (1997, *Clin. Chem.* 43: 2114-2120), or Schneeberger *et al.* (1996, *Anticancer Res.* 16: 849-852), these references incorporated herein by reference in their entirety.

In a preferred embodiment, RT-PCR for c-myc mRNA is performed by the method of Kraehn *et al.* (2001, *Br. J. Cancer* 84: 72-79), incorporated herein by reference in its entirety, using 5 microliters of c-myc cDNA in a PCR reaction mixture containing PCR buffer, 1.5 mM Mg²⁺, 0.2 mM each dNTP, 1.7 Units Taq polymerase (Boehringer, Mannheim, Germany), and 0.5 microM each c-myc primer (SEQ ID Nos. 13 and 14, identified above). The mixture is amplified in a thermocycler under a temperature profile consisting of an initial 4 minute denaturation at 94 degrees C, followed by 45 cycles of denaturation at 93 degrees C for 35 seconds, annealing at 60 degrees C for 35 seconds, and extension at 72 degrees C for 35 seconds, followed by a final extension at 68 degrees C for 10 minutes. Detection of the amplified product is achieved, for example by gel electrophoresis through a 2% agarose gel, using ethidium bromide staining for visualization and identification of the amplified product.

In alternative preferred embodiments, qualitative or quantitative amplification for c-myc mRNA or cDNA is performed by other methods known to the art, *for example*, methods described by Gamberi *et al.* (1998, *Oncology* 55: 556-563), Sagawa *et al.* (2001, *Cancer Letters* 168: 45-50), Christoph *et al.* (1999, *Int. J. Cancer* 84: 169-173), and Latil *et al.* (2000, *Int. J. Cancer* 89: 172-176), these references incorporated herein by reference in their entirety.

In a preferred embodiment, RT-PCR for hnRNP A2/B1 RNA is performed by the method of Zhou *et al.* (1996, *J. Biol. Chem.* 271: 10760-10766), incorporated herein by reference in its entirety, but wherein 5 microliters of cDNA is used in the reaction mixture, and the PCR amplification is performed for 45 cycles. The amplified product is then detected by gel electrophoresis through a 2% agarose gel using ethidium bromide staining for visualization and

identification of the product. In alternative preferred embodiments, qualitative or quantitative amplification of hnRNP A2/B1 RNA, or associated RNA such as hnRNP A2 RNA or hnRNP B1 RNA is performed by other methods known to the art, *for example*, methods described by Kozu *et al.* (1995, *Genomics* 25: 365-371), incorporated by reference herein in its entirety.

5 In alternative preferred embodiments, amplified EGF, EGFr, her-2/neu, c-myc, or hnRNP A2/B1 RNA or any combination thereof or cDNA products thereof can be detected using methods, including but not limited to other gel electrophoresis methods; capillary electrophoresis; ELISA or modifications thereof, such as amplification using biotinylated or otherwise modified primers; nucleic acid hybridization using specific, detectably-labeled probes,
10 such as fluorescent-, radioisotope-, or chromogenically-labeled probes; Southern blot analysis; Northern blot analysis; electrochemiluminescence; laser-induced fluorescence; reverse dot blot detection; and high-performance liquid chromatography. Furthermore, amplified product fragment detection may be performed in either a qualitative or quantitative fashion.

PCR product fragments produced using the methods of the invention can be further
15 cloned into recombinant DNA replication vectors using standard techniques. RNA can be produced from cloned PCR products, and in some instances the RNA expressed thereby, *for example*, using the TnT Quick Coupled Transcription/Translation kit (Promega, Madison, Wisconsin) as directed by the manufacturer.

In another embodiment, restriction digestion may be performed upon a single-stage RT-
20 PCR product. The products of the restriction digestion can be further amplified in a second stage amplification reaction using appropriate primers.

In a preferred embodiment, EGF, EGFr, her-2/neu, c-myc, or hnRNP A2/B1 RNA or any combination thereof or cDNA produced therefrom is amplified in a quantitative fashion thereby

enabling comparison of the amount of said extracellular mRNA in an individual's bodily fluid with the range of amounts of said mRNA present in the bodily fluids of populations with cancer, premalignancy, or normal populations without cancer.

The methods of the invention as described above is not limited to blood plasma or serum, and can be performed in like manner for detecting extracellular EGF, EGFr, her-2/neu, c-myc, or hnRNP A2/B1 RNA or any combination thereof from other bodily fluids, including but not limited to whole blood, urine, effusions, ascitic fluid, saliva, cerebrospinal fluid, cervical secretions, vaginal secretions, endometrial secretions, amniotic fluid, gastrointestinal secretions, breast fluid or secretions, and bronchial secretions including sputum. Whereas fractionation of the bodily fluid into its cellular and non-cellular components is not required for the practice of the invention, the non-cellular fraction may be separated, for example, by centrifugation or filtration of the bodily fluid.

The methods of the invention are useful in the practice of diagnostic methods for detecting extracellular mRNA in an animal, most preferably a human at risk for developing or who has developed a premalignant or malignant neoplastic disease comprising cells expressing EGF, EGFr, her-2/neu, c-myc, or hnRNP A2/B1 RNA or any combination thereof. The invention further provides a method of identifying animals, particularly humans at risk for developing, or who have developed premalignancies or cancer of epithelial tissues and components of tissues, including but not limited to breast, ovarian, lung, cervical, colorectal, gastric, pancreatic, bladder, prostate, head and neck, endometrial, kidney, and esophageal cancers, as well as premalignancies and carcinoma in-situ including but not limited to cervical dysplasia and cervical intraepithelial neoplasia (CIN), bronchial dysplasia, atypical hyperplasia

of the breast, ductal carcinoma in-situ, colorectal adenoma, atypical endometrial hyperplasia, and Barrett's esophagus.

The diagnostic methods of the invention can be advantageously performed using a diagnostic kit as provided by the invention, wherein the kit includes oligonucleotide primers
5 specific for cDNA synthesis of EGF, EGFr, her-2/neu, c-myc, or hnRNP A2/B1 RNA or any combination thereof, or *in vitro* amplification or both, or specific probes, most preferably oligonucleotide probes for detecting EGF, EGFr, her-2/neu, c-myc, or hnRNP A2/B1 RNA or associated hnRNP A2 or B1 RNA or any combination thereof or corresponding cDNA or *in vitro* amplified DNA fragments thereof. The kit can further include methods and reagents for
10 extracting extracellular RNA from a bodily fluid, wherein the bodily fluid is most preferably but not limited to blood plasma or serum. The kit can further comprise reagents for reverse-transcribing said RNA into cDNA or reagents for performing *in vitro* amplification. The kit can further comprise instructions for performing methods for extracting RNA from the bodily fluid, reverse-transcribing said RNA into cDNA or for performing *in vitro* amplification.

15 The inventive methods have significant advantages in assigning and monitoring therapies not specifically directed at cells expressing EGF, EGFr, her-2/neu, c-myc, or hnRNP A2/B1 or any combination thereof, including chemotherapy, radiation therapy, and surgery. The inventive methods further have significant advantages in assigning and monitoring therapies directed at cells expressing EGF, EGFr, her-2/neu, c-myc, or hnRNP A2/B1 or any combination thereof,
20 such as specific or directed therapies such as monoclonal antibody therapies directed at EGFr or her-2/neu, exemplified by Herceptin (Genentech), a her-2/neu-directed monoclonal antibody, and C225 (ImClone Systems), an EGFr-directed monoclonal antibody, or tyrosine kinase inhibitors and small molecule therapies, anti-sense therapies, and vaccine therapies. The methods of the

invention permit stratification and selection of individuals, particularly individual human patients likely to benefit from these specific or directed therapies. The inventive methods are also useful for monitoring response, relapse, and prognosis of neoplastic disease associated with expression of EGF, EGFr, her-2/neu, c-myc, or hnRNP A2/B1 or any combination thereof. Of particular value, the invention allows a determination that a directed therapy is therapeutically indicated even in cases of premalignancy, early cancer, or occult cancers or minimum residual disease, as well as when metastatic disease is present. Thus, the invention permits therapeutic intervention when tumor burden is low, immunologic function is relatively intact, and the patient is not compromised, all increasing the potential for cure.

The methods of the invention further enable RNA encoding EGF, EGFr, her-2/neu, c-myc, or hnRNP A2/B1, or any combination thereof, to be evaluated in blood plasma, serum or other bodily fluid in combination with detection of other tumor-associated or tumor-derived RNA or DNA in a concurrent or sequential fashion, such as in a multiplexed assay or in a chip-based assay, thereby increasing the sensitivity or efficacy of the assay in the detection or monitoring of neoplastic disease. For example, EGF, EGFr, her-2/neu, c-myc, or hnRNP A2/B1 RNA, or any combination thereof can be detected in blood, plasma, serum, or other bodily fluid in combination with detection of telomerase-associated RNA such as hTR and/or hTERT, or in combination with detection of cancer-associated viral DNA such as human papillomavirus DNA, or in combination with oncogene DNA such as mutated K-ras DNA, or in combination with tumor suppressor gene DNA such as altered P53 or APC DNA and/or in combination with microsatellite DNA.

The methods of the invention and preferred uses for the methods of the invention are more fully illustrated in the following Examples. These Examples illustrate certain aspects of

the above-described method and advantageous results. These Examples are shown by way of illustration and not by way of limitation.

EXAMPLE 1

5 A 44 year old woman is diagnosed with metastatic breast cancer and seeks the recommendation of her physician regarding future treatment. The physician draws a peripheral blood specimen from the woman, and evaluates her plasma for the presence of her-2/neu RNA using the methods of the invention. Her-2/neu RNA is demonstrated in the woman's plasma, thereby selecting the woman for a her-2/neu directed therapy. The woman is treated with a
10 monoclonal antibody that binds with the extracellular domain of her-2/neu, and additionally is treated with a cytotoxic chemotherapeutic agent such as a taxane that is known to be synergistic with the monoclonal antibody. The woman's response to therapy is consequently determined by serially monitoring in a quantitative fashion levels of her-2/neu RNA in the women's plasma or serum.

EXAMPLE 2

15 A 56 year old man is being evaluated for his best treatment option after being diagnosed with colorectal cancer. Serum is obtained from the man's peripheral blood and is quantitatively evaluated for the level of EGFr RNA in the serum using the methods of the invention. It is
20 thereby demonstrated that the man has higher levels of EGFr RNA in his blood than would be normally expected, and he is consequently treated with a monoclonal antibody that binds to the extracellular domain of the epidermal growth factor receptor. His response to therapy is

monitored through serial determinations of the quantitative levels of EGFr RNA in his plasma or serum.

EXAMPLE 3

5 A 60 year old man with a long history of smoking presents to his family physician with a complaint of increasing shortness of breath. The physician obtains a chest x-ray that demonstrates a large pleural effusion. The physician subsequently inserts a needle into the pleural space thereby aspirating pleural fluid, which he further evaluates for the presence of tumor cells and for extracellular tumor-associated RNA. Cytology is performed on the fluid but
10 no tumor cells are diagnosed. The fluid is further centrifuged, and the non-cellular component of the pleural fluid is analyzed in multiplexed fashion using the methods of the invention for extracellular her-2/neu RNA, hnRNP A2/B1 RNA, c-myc RNA, and additionally the telomerase RNA hTERT and mutant K-ras DNA. The pleural fluid demonstrates the presence of her-2/neu RNA, hnRNP A2/B1 RNA, and hTERT RNA. The presence of said RNA in the man's pleural
15 fluid strongly supports the diagnosis of a neoplastic disease of the lung. The man subsequently undergoes further radiologic evaluation including magnetic resonance imaging (MRI) and bronchoscopy with biopsy, thereby confirming the diagnosis of lung cancer. The man is treated by surgical resection, followed by treatment with a her-2/neu directed monoclonal antibody in combination with cytotoxic chemotherapy and radiotherapy.

20 While various embodiments of the present invention have been described in detail, it is apparent that modifications and adaptations of those embodiments will occur to those skilled in the art. It is to be expressly understood, however, that such modifications and adaptations are within the scope of the present invention, as set forth in the following claims.

What is claimed is:

1. A method for detecting tumor-derived or tumor-associated RNA in the plasma or serum fraction of blood from a human or animal, wherein the tumor-derived or tumor-associated RNA is epidermal growth factor RNA, epidermal growth factor receptor RNA, her-2/neu RNA, c-myc RNA, heterogeneous nuclear ribonucleoprotein A2/B1 RNA or any combination thereof, the method comprising the steps of:
 - a) extracting mammalian RNA from plasma or serum, wherein a fraction of said extracted RNA comprises a tumor-derived or tumor-specific RNA species that is epidermal growth factor RNA, epidermal growth factor receptor RNA, her-2/neu RNA, c-myc RNA, heterogeneous nuclear ribonucleoprotein A2/B1 RNA or any combination thereof;
 - b) amplifying or signal amplifying said fraction of the extracted RNA or corresponding cDNA prepared therefrom, wherein amplification is performed in either a qualitative or quantitative fashion using primers specific for the tumor-derived or tumor-associated RNA or cDNA corresponding thereto to produce an amplified product; and
 - c) detecting the amplified product produced from the RNA or cDNA.
2. A method for detecting extracellular tumor-derived or tumor-associated RNA in a bodily fluid from a human or animal, wherein the tumor-derived or tumor-associated RNA is epidermal growth factor RNA, epidermal growth factor receptor RNA, her-2/neu RNA,

c-myc RNA, heterogeneous nuclear ribonucleoprotein A2/B1 RNA or any combination thereof, the method comprising the steps of:

- a) extracting mammalian RNA from a bodily fluid, wherein a fraction of said extracted RNA comprises an extracellular tumor-derived or tumor-specific RNA species that is epidermal growth factor RNA, epidermal growth factor receptor RNA, her-2/neu RNA, c-myc RNA, heterogeneous nuclear ribonucleoprotein A2/B1 RNA or any combination thereof;
- b) amplifying or signal amplifying said fraction of the extracted RNA or cDNA corresponding thereto, wherein amplification is performed in either a qualitative or quantitative fashion using primers or probes specific for the tumor-derived or tumor-associated RNA or cDNA corresponding thereto to produce an amplified product; and
- c) detecting the amplified product produced from the RNA or cDNA corresponding thereto.

3. The method of claim 1, wherein the amplification in step (b) is performed by a RNA amplification method that amplifies the RNA directly or wherein the RNA is first reverse transcribed to cDNA whereby the cDNA is amplified, and wherein the amplification method is reverse transcriptase polymerase chain reaction, ligase chain reaction, branched DNA signal amplification, amplifiable RNA reporters, Q-beta replication, transcription-based amplification, isothermal nucleic acid sequence-based amplification, self-sustained sequence replication assay, boomerang DNA amplification, strand displacement activation, or cycling probe technology.

4. The method of claim 2, wherein the amplification in step (b) is performed by a RNA
amplification method that amplifies the RNA directly or wherein the RNA is first reverse
transcribed to cDNA whereby the cDNA is amplified, and wherein the amplification
5 method is reverse transcriptase polymerase chain reaction, ligase chain reaction,
branched DNA signal amplification, amplifiable RNA reporters, Q-beta replication,
transcription-based amplification, isothermal nucleic acid sequence-based amplification,
self-sustained sequence replication assay, boomerang DNA amplification, strand
displacement activation, or cycling probe technology.

10
5. The method of claim 1, wherein detection of the amplified product in step (c) is
performed using a detection method that is gel electrophoresis, capillary electrophoresis,
ELISA detection including using biotinylated or other modified primers, labeled
fluorescent or chromagenic probes, laser-induced fluorescence, Southern blot analysis,
15 Northern blot analysis, electroluminescence, reverse blot detection, or high-performance
liquid chromatography.

20
6. The method of claim 2, wherein detection of the amplified product in step (c) is
performed using a detection method that is gel electrophoresis, capillary electrophoresis,
ELISA detection including using biotinylated or other modified primers, labeled
fluorescent or chromagenic probes, laser-induced fluorescence, Southern blot analysis,
Northern blot analysis, electroluminescence, reverse blot detection, or high-performance
liquid chromatography.

7. The method of claim 1, wherein the RNA in step (a) is extracted from plasma or serum using an RNA extraction method that is a gelatin extraction method; silica, glass bead or diatom extraction method; guanidine-thiocyanate-phenol solution extraction method; 5 guanidinium thiocyanate acid-based extraction method; phenol-chloroform-based extraction method; or involves centrifugation through a cesium chloride or similar gradient.

8. The method of claim 2, wherein the RNA in step (a) is extracted from a bodily fluid 10 using an RNA extraction method that is a gelatin extraction method; silica, glass bead, or diatom extraction method; guanidine-thiocyanate-phenol solution extraction method; guanidinium thiocyanate acid-based extraction method; phenol-chloroform-based extraction method; or involves centrifugation through a cesium chloride or similar gradient.

15 9. The method for screening an animal for malignancy or premalignancy associated with epidermal growth factor RNA, epidermal growth factor receptor RNA, her-2/neu RNA, c-myc RNA, or heterogeneous nuclear ribonucleoprotein A2/B1 RNA or any combination thereof, the method comprising the steps of performing the method of claim 20 1 qualitatively or quantitatively, and detecting a product produced by said RNA in the plasma or serum of said animal or human, wherein detection of said RNA indicates that malignant or premalignant cells are present in the body of said animal or human.

10. The method for screening an animal for malignancy or premalignancy associated with epidermal growth factor RNA, epidermal growth factor receptor RNA, her-2/neu RNA, c-myc RNA, or heterogeneous nuclear ribonucleoprotein A2/B1 RNA or any combination thereof, the method comprising the steps of performing the method of claim 2 qualitatively or quantitatively, and detecting a product produced by said RNA in the plasma or serum of said animal or human, wherein detection of said RNA indicates that malignant or premalignant cells are present in the body of said animal or human.

11. A method according to claim 9 wherein the animal is a human

12. A method according to claim 10 wherein the animal is a human

13. A method of identifying an animal or human having EGF, EGFr, her-2/neu, c-myc, or hnRNP A2/B1 expressing cells or tissue, the method comprising the steps of:

- a) extracting mammalian RNA from a bodily fluid of the animal or human;
- b) amplifying a fraction of the extracted RNA or cDNA corresponding thereto, wherein said fraction comprises EGF RNA, EGFr RNA, her-2/neu RNA, c-myc RNA, or hnRNP A2/B1 RNA or any combination thereof, and wherein amplification is performed qualitatively or quantitatively using primers specific for the RNA or cDNA corresponding thereto to produce an amplified product; and
- c) detecting the amplified product produced from the RNA or cDNA corresponding thereto, whereby detection thereby identifies a human having EGF RNA, EGFr

RNA, her-2/neu RNA, c-myc RNA, or hnRNP A2/B1 RNA expressing cells or tissue.

14. The method of claim 13, wherein the EGF RNA, EGFr RNA, her-2/neu RNA, c-myc
5 RNA, or hnRNP A2/B1 RNA expressing cells or tissue comprise a malignancy, or premalignancy, or carcinoma in situ.
15. The method of claim 13, wherein the animal or human is one having a risk for
developing a malignancy or premalignancy.
- 10 16. The method of claim 13, wherein the animal or human has been diagnosed as having a malignancy, premalignancy or carcinoma in situ.
- 15 17. A method for detecting or diagnosing a disease associated with expression of epidermal growth factor RNA, epidermal growth factor receptor RNA, her-2/neu RNA, c-myc RNA, or heterogeneous nuclear ribonucleoprotein A2/B1 RNA .in an animal, the method comprising the steps of detecting an amplified product according to claim 1 and
detecting or diagnosing a disease associated with expression of epidermal growth factor
RNA, epidermal growth factor receptor RNA, her-2/neu RNA, c-myc RNA, or
20 heterogeneous nuclear ribonucleoprotein A2/B1 RNA.
18. A method for detecting or diagnosing a disease associated with expression of epidermal growth factor RNA, epidermal growth factor receptor RNA, her-2/neu RNA, c-myc

RNA, or heterogeneous nuclear ribonucleoprotein A2/B1 RNA. in an animal, the method comprising the steps of detecting an amplified product according to claim 2 and detecting or diagnosing a disease associated with epidermal growth factor RNA, epidermal growth factor receptor RNA, her-2/neu RNA, c-myc RNA, or heterogeneous nuclear ribonucleoprotein A2/B1 RNA.

19. The method of claim 17 wherein the disease is a malignancy or premalignancy.

20. The method of claim 18 wherein the disease is a malignancy or premalignancy.

21. A method for monitoring an animal or human for a malignant or premalignant disease, wherein the malignant or premalignant disease is associated with a tumor-derived or tumor-associated RNA that is epidermal growth factor RNA, epidermal growth factor receptor RNA, her-2/neu RNA, c-myc RNA, or heterogeneous nuclear ribonucleoprotein A2/B1 RNA, or any combination thereof, the method comprising the step of:

- 1) detecting RNA associated with the malignant or premalignant disease qualitatively or quantitatively, wherein the RNA is epidermal growth factor RNA, epidermal growth factor receptor RNA, her-2/neu RNA, c-myc RNA, or heterogeneous nuclear ribonucleoprotein A2/B1 RNA or any combination thereof, according to a method comprising the steps of:
 - a) extracting mammalian RNA from plasma or serum, wherein a fraction of said extracted RNA comprises epidermal growth factor RNA, epidermal growth factor

receptor RNA, her-2/neu RNA, c-myc RNA, heterogeneous nuclear ribonucleoprotein A2/B1 RNA or any combination thereof;

- b) amplifying or signal amplifying said fraction of the extracted RNA or corresponding cDNA, wherein amplification is performed qualitatively or quantitatively using primers specific for the tumor-derived or tumor-associated RNA or cDNA corresponding thereto, to produce an amplified product; and
- c) detecting the amplified product produced from RNA or cDNA corresponding thereto.

22. A method for monitoring an animal or human for a malignant or premalignant disease, wherein the malignant or premalignant disease is associated with tumor-derived or tumor-associated RNA that is epidermal growth factor RNA, epidermal growth factor receptor RNA, her-2/neu RNA, c-myc RNA, or heterogeneous nuclear ribonucleoprotein A2/B1 RNA or any combination thereof, the method comprising the step of:

- 1) detecting qualitatively or quantitatively RNA associated with the malignant or premalignant disease, wherein the RNA is epidermal growth factor RNA, epidermal growth factor receptor RNA, her-2/neu RNA, c-myc RNA, or heterogeneous nuclear ribonucleoprotein A2/B1 RNA or any combination thereof, according to a method comprising the steps of:

- a) extracting mammalian RNA from a bodily fluid, wherein a fraction of said extracted RNA comprises epidermal growth factor RNA, epidermal growth factor receptor RNA, her-2/neu RNA, c-myc RNA, heterogeneous nuclear ribonucleoprotein A2/B1 RNA or any combination thereof;

- b) amplifying or signal amplifying said fraction of the extracted RNA or cDNA corresponding thereto, wherein amplification is performed qualitatively or quantitatively using primers specific for the tumor-derived or tumor-associated RNA or cDNA corresponding thereto, to produce an amplified product; and
- 5 c) detecting the amplified product produced from said RNA or cDNA corresponding thereto.

23. A method for selecting an animal or human with cancer for an epidermal growth factor-directed therapy comprising the step of performing the method of claim 1 using blood
10 plasma or serum from said animal or human and selecting the animal or human for an epidermal growth factor-directed therapy when epidermal growth factor RNA is detected in the animal or human's plasma or serum.

24. A method for selecting an animal or human with cancer for an epidermal growth factor-directed therapy comprising the step of performing the method of claim 2 using a bodily
15 fluid from said animal or human and selecting the animal or human for an epidermal growth factor-directed therapy when epidermal growth factor RNA is detected in the animal or human's plasma or serum.

20 25. A method for selecting an animal or human with cancer for an epidermal growth factor receptor-directed therapy comprising the step of performing the method of claim 1 using blood plasma or serum from said animal or human and selecting the animal or human for

an epidermal growth factor-directed therapy when epidermal growth factor receptor RNA is detected in the animal or human's plasma or serum.

26. A method for selecting an animal or human with cancer for an epidermal growth factor receptor-directed therapy comprising the step of performing the method of claim 2 using a bodily fluid from said animal or human and selecting the animal or human for an epidermal growth factor-directed therapy when epidermal growth factor receptor RNA is detected in the animal or human's plasma or serum.

27. A method for selecting an animal or human with cancer for a her-2/neu-directed therapy comprising the step of performing the method of claim 1 using blood plasma or serum from said animal or human and selecting the animal or human for an epidermal growth factor-directed therapy when her-2/neu RNA is detected in the animal or human's plasma or serum.

28. A method for selecting an animal or human with cancer for a her-2/neu-directed therapy comprising the step of performing the method of claim 2 using a bodily fluid from said animal or human and selecting the animal or human for an epidermal growth factor-directed therapy when her-2/neu RNA is detected in the animal or human's plasma or serum..

29. The method of claim 23 wherein the therapy is a monoclonal antibody or a tyrosine kinase inhibitor.

30. The method of claim 24 wherein the therapy is a monoclonal antibody or a tyrosine kinase inhibitor.

5 31. The method of claim 25 wherein the therapy is a monoclonal antibody or a tyrosine kinase inhibitor.

32. The method of claim 26 wherein the therapy is a monoclonal antibody or a tyrosine kinase inhibitor.

10

33. The method of claim 27 wherein the therapy is a monoclonal antibody or a tyrosine kinase inhibitor.

15 34. The method of claim 28 wherein the therapy is a monoclonal antibody or a tyrosine kinase inhibitor.

35. A method for selecting an animal or human with cancer for a cancer-directed therapy, the method comprising the steps of:

- 20 a) extracting mammalian RNA from plasma or serum of the animal or human, wherein a fraction of said extracted RNA comprises a tumor-derived or tumor-specific RNA that is epidermal growth factor RNA, epidermal growth factor receptor RNA, her-2/neu RNA, c-myc RNA, or heterogeneous nuclear ribonucleoprotein A2/B1 RNA or any combination thereof;

- b) amplifying or signal amplifying said fraction of the extracted RNA or cDNA corresponding thereto, wherein amplification is performed qualitatively or quantitatively using primers specific for the tumor-derived or tumor-associated RNA or cDNA corresponding thereto to produce an amplified product; and
- 5 c) detecting the amplified product produced from said RNA or cDNA, whereby detection thereof selects the human with cancer for a cancer directed therapy.

36. A method according to claim 1, further comprising the step of performing a diagnostic test for diagnosing cancer or premalignancy when epidermal growth factor RNA,
10 epidermal growth factor receptor RNA, her-2/neu RNA, c-myc RNA, heterogeneous nuclear ribonucleoprotein A2/B1 RNA or any combination thereof is detected in plasma or serum of an animal or human.

37. A method according to claim 2, further comprising the step of performing a diagnostic
15 test for diagnosing cancer or premalignancy when epidermal growth factor RNA, epidermal growth factor receptor RNA, her-2/neu RNA, c-myc RNA, heterogeneous nuclear ribonucleoprotein A2/B1 RNA or any combination thereof is detected in a bodily fluid of an animal or human.

20 38. The method of claim 35, wherein the cancer-directed therapy is surgery, chemotherapy, biologic therapy, vaccine therapy, anti-angiogenic therapy, or radiotherapy.

39. The method of claim 35, wherein the cancer-directed therapy is monoclonal antibody therapy or tyrosine kinase inhibitor therapy.

5 40. A method for monitoring response to an anticancer therapy, comprising the step of performing the method of claim 1 on blood plasma or serum from an animal or human with cancer to whom anticancer therapy is administered, and wherein response to the anticancer therapy is accomplished by qualitative or quantitative detection of epidermal growth factor RNA, epidermal growth factor receptor RNA, her-2/neu RNA, c-myc RNA, heterogeneous nuclear ribonucleoprotein A2/B1 RNA or any combination thereof.

10 41. A method for monitoring response to an anticancer therapy, comprising the step of performing the method of claim 2 on a bodily fluid from an animal or human with cancer to whom anticancer therapy is administered, and wherein response to the anticancer therapy is accomplished by qualitative or quantitative detection of epidermal growth factor RNA, epidermal growth factor receptor RNA, her-2/neu RNA, c-myc RNA, heterogeneous nuclear ribonucleoprotein A2/B1 RNA or any combination thereof.

15 42. A diagnostic kit comprising primers specific for amplifying epidermal growth factor RNA or cDNA prepared therefrom and reagents for extracting RNA from plasma or serum according to the method of claim 1.

20

43. A diagnostic kit comprising primers specific for amplifying epidermal growth factor receptor RNA or cDNA prepared therefrom and reagents for extracting RNA from plasma or serum according to the method of claim 1.

5 44. A diagnostic kit comprising primers specific for amplifying her-2/neu RNA or cDNA prepared therefrom and reagents for extracting RNA from plasma or serum according to the method of claim 1.

10 45. A diagnostic kit comprising primers specific for amplifying c-myc RNA or cDNA prepared therefrom and reagents for extracting RNA from plasma or serum according to the method of claim 1.

15 46. A diagnostic kit comprising primers specific for amplifying heterogeneous nuclear ribonucleoprotein A2/B1 RNA or cDNA prepared therefrom and reagents for extracting RNA from plasma or serum according to the method of claim 1.

20 47. A diagnostic kit comprising primers specific for amplifying epidermal growth factor RNA or cDNA prepared therefrom and reagents for extracting RNA from a bodily fluid according to the method of claim 2.

48. A diagnostic kit comprising primers specific for amplifying epidermal growth factor receptor RNA or cDNA prepared therefrom and reagents for extracting RNA from a bodily fluid according to the method of claim 2.

49. A diagnostic kit comprising primers specific for amplifying her-2/neu RNA or cDNA prepared therefrom and reagents for extracting RNA from a bodily fluid according to the method of claim 2.
- 5
50. A diagnostic kit comprising primers specific for amplifying c-myc RNA or cDNA prepared therefrom and reagents for extracting RNA from a bodily fluid according to the method of claim 2.
- 10 51. A diagnostic kit comprising primers specific for amplifying heterogeneous nuclear ribonucleoprotein A2/B1 RNA or cDNA prepared therefrom and reagents for extracting RNA from a bodily fluid according to the method of claim 2.
- 15 52. A method for producing cDNA by reverse transcription of a fraction of extracellular mammalian RNA extracted from plasma or serum, wherein the fraction comprises epidermal growth factor RNA, epidermal growth factor receptor RNA, her-2/neu RNA, c-myc RNA, heterogeneous nuclear ribonucleoprotein A2/B1 RNA, or any combination thereof, whereby cDNA corresponding to said RNA is produced.
- 20 53. A method for producing cDNA by reverse transcription of a fraction of extracellular mammalian RNA extracted from a bodily fluid, wherein the fraction comprising epidermal growth factor RNA, epidermal growth factor receptor RNA, her-2/neu RNA, c-myc RNA,

heterogeneous nuclear ribonucleoprotein A2/B1 RNA, or any combination thereof, whereby cDNA corresponding to said RNA is produced.

SEQUENCE LISTING

<110> Kopreski, Michael S

<120> Method enabling use of extracellular RNA extracted from plasma or serum to detect, monitor or evaluate cancer

<130> 09966515

<140> PCT/US

<141> 2002-09-26

<150> 09/966,515

<151> 2001-09-28

<160> 15

<170> PatentIn Ver. 2.1

<210> 1

<211> 31

<212> DNA

<213> Homo sapiens

<400> 1
tctcaacaca tgctagtggc tgaaatcatg g 31

<210> 2

<211> 31

<212> DNA

<213> Homo sapiens

<400> 2
tcaatataca tgcacacacc atcatggagg c 31

<210> 3

<211> 31

<212> DNA

<213> Homo sapiens

<400> 3
tcaatataca tgcacacacc atcatggagg c 31

<210> 4

<211> 20

<212> DNA

<213> Homo sapiens

<400> 4
tctcagcaac atgtcgatgg 20

<210> 5

<211> 20

<212> DNA
<213> Homo sapiens

<400> 5
tcgcacttct tacacttgcg

20

<210> 6
<211> 20
<212> DNA
<213> Homo sapiens

<400> 6
tcacatccat ctggtacgtg

20

<210> 7
<211> 24
<212> DNA
<213> Homo sapiens

<400> 7
gagacggagc tgaggaaggt gaag

24

<210> 8
<211> 22
<212> DNA
<213> Homo sapiens

<400> 8
ttccagcagg tcagggatct cc

22

<210> 9
<211> 20
<212> DNA
<213> Homo sapiens

<400> 9
caaccaagtg aggcagggtcc

20

<210> 10
<211> 21
<212> DNA
<213> Homo sapiens

<400> 10
ggtctccatt gtctagcacg g

21

<210> 11
<211> 20
<212> DNA
<213> Homo sapiens

<400> 11 agaggctgcg gattgtgcga	20
<210> 12 <211> 18 <212> DNA <213> Homo sapiens	
<400> 12 ccagcagcga ctctgagg	18
<210> 13 <211> 18 <212> DNA <213> Homo sapiens	
<400> 13 ccaagacgtt gtgtgttc	18
<210> 14 <211> 20 <212> DNA <213> Homo sapiens	
<400> 14 gagtccggtt cgtgttcgtc	20
<210> 15 <211> 19 <212> DNA <213> Homo sapiens	
<400> 15 tggcagcatc aacctcagc	19

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 April 2003 (10.04.2003)

PCT

(10) International Publication Number
WO 2003/028531 A3

(51) International Patent Classification:
C12P 19/34 (2006.01) *C07H 21/02* (2006.01)

(21) International Application Number:
PCT/US2002/030485

(22) International Filing Date:
26 September 2002 (26.09.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
09/966,515 28 September 2001 (28.09.2001) US

(63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 09/966,515 (CON)
Filed on 28 September 2001 (28.09.2001)

(71) Applicant (for all designated States except US): ON-COMEDX, INC. [US/US]; 23 Wellington Drive, Long Valley, NJ 07853 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): KOPRESKI, Michael [US/US]; 23 Wellington Drive, Long Valley, NJ 07853 (US).

(74) Agent: NOONAN, Kevin; McDonnell Boehnen Hulbert & Berghoff, 300 South Wacker Drive, Chicago, IL 60606 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
28 September 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DETECTION OF TUMOR RNA IN PLASMA AND SERUM

(57) Abstract: The methods of the invention detect epidermal growth factor RNA, epidermal growth factor receptor RNA, her-2/neu RNA, c-myc RNA, heterogeneous nuclear ribonucleoprotein A2/B1 or any combination thereof in blood plasma, serum, and other bodily fluids. The inventive methods are useful for detection, diagnosis, monitoring, treatment, or evaluation of neoplastic disease.

WO 2003/028531 A3

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/30485

A. CLASSIFICATION OF SUBJECT MATTER

IPC: C12P 19/34(2006.01)
C07H 21/02(2006.01)

USPC: 435/91.2

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 435/6, 91.1, 91.2, 183; 436/94; 536/23.1, 24.3, 24.33, 25.3, 25.32

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	KOPRESKI et al. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clinical Cancer Research. August 1999, Vol. 5, pages 1961-1965, especially see pages 1964 and 1965.	1-12, 21, 36, 37, 40, 41, and 53
Y	LEITZEL et al. Detection of cancer cells in peripheral blood of breast cancer patients using reverse transcription-polymerase chain reaction for epidermal growth factor receptor. Clinical Cancer Research. December 1998, Vol. 4, pages 3037-3043, see entire document.	1-12, 21, 36, 37, 40, 41, and 53
A,P	US 6,329,179 B1 (KOPRESKI) 11 December 2001, (11.12.2001), see whole document, especially see claims 1-24 in columns 21-28.	1-12, 21, 36, 37, 40, 41, and 53

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search

07 July 2006 (07.07.2006)

Date of mailing of the international search report

01 AUG 2006

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner of Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Authorized officer

Frank Lu

Telephone No. 571-272-1600

Facsimile No. (571) 273-3201

Form PCT/ISA/210 (second sheet) (July 1998)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/30485

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: 1-12,21,36,37,40,41 and 53

Remark on Protest ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claims 1-12, 21, 36, 37, 40, 41, and 53, drawn to a method for detecting tumor-derived or tumor-associated RNA in the plasma or serum fraction of blood (claims 1, 3, 5, 7, 9, 11 and 36), a method for detecting extracellular tumor-derived or tumor-associated RNA in a bodily fluid (claims 2, 4, 6, 8, 10, 12, and 37), a method for monitoring an animal or human for a malignant or premalignant disease (claim 21), a method for monitoring response to an anticancer therapy (claims 40 and 41), a diagnostic kit (claim 42-51), and a method for producing cDNA of epidermal growth factor by reverse transcription (claims 52 and 53).

Group II, claims 13-16 and 22, drawn to a method for identifying an animal or human having EGF, EGFR, her-2/neu, c-myc, or hnRNP A2/B1 expressing cells or tissue (claims 13-16), method for monitoring an animal or human for a malignant or premalignant disease (claim 22).

Group III, claims 17-20, drawn to a method for detecting or diagnosing a disease associated with expression of tumor-derived or tumor-associated RNA.

Group IV, claims 23-28 and 35, drawn to a method for selecting an animal or human with cancer for a therapy.

Group V, claims 29-34, 38, and 39, drawn to a method for a therapy.

Group VI, claims 42-52, drawn to a kit.

The inventions listed as Groups I to VI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons:

Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features. For example, the search required for Group I such as extracellular tumor-derived or tumor-associated RNA of claim 2 is not required for Group II.

Groups I and III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features. For example, the search required for Group III such as diagnosing a disease associated with tumor-derived or tumor-associated RNA of claim 17 is not required for Group I.

Groups I and IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features. For example, the search required for Group IV such as selecting an animal or human for therapy of claim 23 is not required for Group I.

Groups I and V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features. For example, the search required for Group V such as therapy methods of claim 29 is not required for Group I.

Groups II and III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features. For example, the search required for Group III such as diagnosing a disease associated with tumor-derived or tumor-associated RNA of claim 17 is not required for Group II.

Groups II and IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features. For example, the search required for Group IV such as selecting an animal or human for therapy of claim 23 is not required for Group II.

Groups II and V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features. For example, the search required for Group V such as therapy methods of claim 29 is not required for Group II.

Groups III and IV do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features. For example, the search required for Group IV such as selecting an animal or human for therapy of claim 23 is not required for Group III.

Groups III and V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features. For example, the search required for Group V such as the therapy method of claim 29 is not required for Group III.

Groups IV and V do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features. For example, the search required for Group V such as the therapy method of claim 29 is not required for Group IV.

Groups I to V and Group VI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features. For example, the search required for Groups I to V such as amplifying

INTERNATIONAL SEARCH REPORT

PCT/US02/30485

mRNA from plasma or serum is not required for Group VI while the search required for Group VI such as a kit is not required for Groups I to V.

Continuation of B. FIELDS SEARCHED Item 3:

STN and EAST

Search Terms: Plasma or serum, RNA, isolate or isolation, tumor or cancer, amplify or amplification and detect or detection